The ANSWER study (not placebo-controlled) has investigated the effects of weekly albumin infusion (40 g twice weekly for 2 weeks followed by 40 g per week) for 18 months in patients with uncomplicated ascites and revealed that patients receiving albumin exhibited better ascites control (hazard ratio [HR] of 0.48 for the incidence of paracentesis, HR of 0.43 for developing refractory ascites), a decreased risk of renal dysfunction (HR of 0.50), and particularly HRS-AKI incidence (HR of 0.39). The gene discussed is ALB; the disease is Abnormal renal physiology.